Highlights
New-onset postoperative atrial fibrillation (POAF) occurred in 31.8% of patients after cardiac surgery in the multinational VISION Cardiac Surgery cohort.
Post-discharge management varied widely: most patients with POAF were discharged on antiplatelet therapy alone, fewer received anticoagulation, and nearly half received amiodarone.
POAF was strongly associated with later clinical atrial fibrillation and with higher all-cause mortality over 1 year, while the association with stroke or vascular death was numerically higher but did not reach conventional statistical significance after adjustment.
The findings reinforce POAF as a clinically important postoperative complication, but also highlight major uncertainty in antithrombotic management after cardiac surgery.
Clinical Background and Unmet Need
New-onset atrial fibrillation after cardiac surgery is one of the most common perioperative complications in cardiovascular medicine. It affects hemodynamic stability, prolongs hospitalization, complicates discharge planning, and raises concern for thromboembolic risk. Yet despite its frequency, the optimal management of POAF remains unsettled. Clinicians must balance several competing considerations: the transient nature of many early postoperative arrhythmias, the potential for recurrent or persistent atrial fibrillation later, and the bleeding risk associated with anticoagulation soon after surgery.
Much of the current evidence base for POAF has come from administrative registries or single-center cohorts, both of which have limitations in the granularity of treatment data, outcome ascertainment, and cross-country generalizability. The VISION Cardiac Surgery cohort was designed to address some of these gaps by prospectively observing patients across multiple centers and countries, with systematic follow-up and adjustment for patient-level and operative variables. This makes the study particularly relevant for clinicians seeking a more robust estimate of both the burden and longer-term implications of POAF.
Study Design
The investigators analyzed data from the VISION Cardiac Surgery cohort, a prospective multicenter study of adults undergoing cardiac surgery in 12 countries. The final analysis included 12,234 patients, 55.3% of whom underwent isolated coronary artery bypass grafting.
POAF was defined as new-onset atrial fibrillation within 30 days of surgery. The authors then examined post-discharge management patterns, including anticoagulation, antiplatelet therapy, combined therapy, no antithrombotic therapy, and use of amiodarone at hospital discharge. Outcomes were assessed between 30 days and 1 year after surgery.
The primary clinical association analysis used a multivariable Cox model adjusted for patient and operative characteristics as well as antithrombotic therapies. Outcomes included clinical AF detected at 1 year, a composite of stroke or vascular death, and all-cause death.
Key Findings
Incidence of POAF
POAF occurred in 31.8% of the overall cohort, confirming that this arrhythmia remains common after cardiac surgery. This incidence is consistent with the widely recognized high burden of postoperative atrial arrhythmias, especially after procedures involving the atria, valve surgery, and more complex operations. In practical terms, roughly one in three patients experienced POAF within the first postoperative month.
Post-Discharge Management Was Highly Variable
Among patients with POAF, discharge antithrombotic strategies varied substantially. Only 15.6% received anticoagulation alone, 54.3% received antiplatelet therapy alone, 23.9% received both anticoagulation and antiplatelets, and 6.3% received neither therapy. Nearly half, 48.8%, were receiving amiodarone.
This heterogeneity is clinically important. It suggests that there is no uniform approach to POAF management in real-world practice, likely reflecting differences in perceived stroke risk, bleeding risk, procedure type, surgeon preference, and local practice patterns. The high use of antiplatelet therapy alone is notable, particularly because antiplatelet agents are not considered equivalent to oral anticoagulation for stroke prevention in atrial fibrillation in general populations. However, POAF is a special case, and uncertainty persists about the duration and intensity of anticoagulation needed after transient postoperative arrhythmia.
Risk of Later Clinical AF
At 1 year, clinical atrial fibrillation was detected in 6.9% of patients with POAF compared with 0.6% of those without POAF. The adjusted hazard ratio was 11.30 (95% confidence interval [CI] 8.17–15.70), indicating a very strong association between early postoperative arrhythmia and later documented atrial fibrillation.
This is perhaps the most actionable signal from the study. POAF should not be viewed purely as a short-lived postoperative event; rather, it may identify a population with underlying atrial vulnerability and a substantially higher likelihood of recurrent or newly recognized AF over time. For clinicians, this supports closer rhythm surveillance after discharge, especially in patients with additional stroke risk factors or in those in whom anticoagulation is not prescribed.
Stroke or Vascular Death
The primary composite outcome of stroke or vascular death occurred in 2.3% of patients with POAF and 1.5% of those without POAF. After adjustment, the hazard ratio was 1.32 (95% CI 0.99–1.77). This estimate suggests a possible increase in risk, but the confidence interval includes no effect and the result did not meet conventional statistical significance.
From a clinical standpoint, this finding is nuanced. It does not eliminate concern about thromboembolic risk after POAF, but it does indicate that the association is likely more modest than many clinicians may assume, at least within the first postoperative year and under the treatment patterns observed in this cohort. It also raises the possibility that routine anticoagulation for every episode of POAF may not be justified without better individualized risk stratification.
All-Cause Mortality
Patients with POAF had a higher 1-year all-cause mortality than those without POAF: 3.0% versus 1.7%. The adjusted hazard ratio was 1.54 (95% CI 1.18–2.00), indicating a statistically significant association.
Importantly, mortality is a nonspecific endpoint. The study does not prove that POAF itself directly causes death; rather, POAF may be a marker of more severe underlying cardiac disease, perioperative stress, inflammation, or postoperative complications not fully captured in adjustment models. Nonetheless, the association reinforces the view that POAF identifies a higher-risk postoperative phenotype and should not be dismissed as benign.
Expert Commentary
This study’s main strength is its prospective, multicenter design across 12 countries, which improves the external validity of the findings compared with single-center series. The sample size was large, the incidence estimates are precise, and the authors attempted to account for confounding by adjusting for patient, operative, and antithrombotic factors. These features make the study highly relevant to everyday cardiac surgical and cardiology practice.
At the same time, several limitations should temper interpretation. First, as an observational study, it cannot establish whether specific management strategies, particularly anticoagulation or amiodarone, improve outcomes. Treatment was not randomized, so confounding by indication remains a major concern. Second, POAF detection and later AF ascertainment may have varied by site and follow-up intensity, potentially underestimating asymptomatic or paroxysmal arrhythmia. Third, the endpoint of clinical AF at 1 year depends on detection, and the true burden may be higher with systematic rhythm monitoring. Fourth, the study cannot fully resolve the long-standing question of optimal anticoagulation duration after POAF, especially for patients with high bleeding risk following surgery.
The findings fit with current uncertainty reflected in major guidelines. Contemporary atrial fibrillation guidance recognizes POAF as a meaningful arrhythmic event, but the decision to anticoagulate remains individualized, commonly guided by AF duration, recurrence, CHA2DS2-VASc stroke risk, and bleeding risk in the immediate postoperative setting. In this context, the VISION cohort supports a more conservative interpretation of universal anticoagulation, while strengthening the case for post-discharge rhythm follow-up and risk reassessment.
Mechanistically, POAF likely reflects a convergence of atrial inflammation, catecholamine surges, perioperative fluid shifts, ischemia-reperfusion injury, and pre-existing atrial substrate. These factors may explain both the early postoperative arrhythmia and the later propensity toward recurrent AF. The observed association with mortality may therefore be less about the arrhythmia episode itself and more about the broader physiological stress and comorbidity burden it signals.
Clinical Implications
For clinicians, several practical points emerge. First, POAF is common and should be anticipated in postoperative care pathways. Second, the heterogeneity in antithrombotic management underscores the need for clearer institutional protocols and more evidence on who should receive anticoagulation, for how long, and in combination with antiplatelet therapy. Third, patients with POAF may benefit from structured follow-up, including reassessment of rhythm status and stroke/bleeding risk after discharge. Fourth, the substantial increase in later clinical AF suggests that POAF should trigger long-term cardiovascular vigilance rather than reassurance alone.
For health systems and policy makers, the study highlights the importance of integrating cardiac surgery follow-up with arrhythmia surveillance infrastructure. Given the burden of postoperative AF, even modest improvements in detection, risk stratification, and treatment selection could have meaningful downstream benefits.
Conclusion
In the VISION Cardiac Surgery cohort, new-onset POAF affected about one-third of patients after cardiac surgery and was associated with variable post-discharge treatment. Patients with POAF had a markedly higher risk of later clinical AF and a significantly higher risk of all-cause death within 1 year, while the adjusted association with stroke or vascular death was directionally higher but not statistically conclusive. The study strengthens the case that POAF is not a trivial postoperative event and should prompt careful follow-up, but it also underscores the lack of definitive evidence for a one-size-fits-all antithrombotic strategy.
Future randomized studies are needed to clarify which patients with POAF truly benefit from anticoagulation, how long treatment should continue, and whether structured rhythm monitoring after discharge can improve clinical outcomes.
Funding and ClinicalTrials.gov
The PubMed record provided for this article does not specify funding details or a ClinicalTrials.gov identifier in the abstract excerpt. Readers should consult the full article in European Heart Journal for complete disclosures and trial registration information, if applicable.
References
1. McIntyre WF, Devereaux PJ, Belley-Cote EP, et al. New-onset postoperative atrial fibrillation management and outcomes: the VISION Cardiac Surgery cohort. European Heart Journal. 2026;47(23):2968-2977. PMID: 41964448.
2. January CT, Wann LS, Calkins H, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation. Circulation. 2024;149:e1-e156.
3. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42:373-498.
4. Bessissow A, Khan J, Devereaux PJ, et al. Postoperative atrial fibrillation in non-cardiac and cardiac surgery: clinical practice and future directions. Heart Rhythm. 2015;12:xxx-xxx. [General background reference; verify page details in full citation databases before use.]